Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.La Jolla Pharmaceutical has said that its treatment for lupus, Riquent, showed a greater reductions in antibodies than placebo in a late stage trial.
Subscribe to our email newsletter
Patients treated with 900mg or 300mg per week doses of Riquent had greater reductions in antibodies than placebo or 100mg per week of Riquent. Following eight weeks of treatment, the median percent reduction in antibodies to dsDNA for was 36% for 100mg, 48% at 300mg, and 66% for 900mg of Riquent.
“The higher the dose, the greater the reduction in antibodies to dsDNA, and the relative magnitude of these reductions is greater than we have seen in previous studies, which used lower doses of Riquent. Higher doses also appear to result in a larger percentage of patients having greater and more consistent antibody reductions over time,” said Deirdre Gillespie, president and CEO of La Jolla Pharmaceutical Company.
La Jolla said the adverse event profile for all patients in the study does not appear to differ from that seen in previous studies where 100mg of Riquent was the treatment dose.